SAMiRNA overcomes two major hurdles in delivery: metabolic clearance of small conjugates and cytoplasmic delivery.
​With a longer serum half-life than a typical conjugate combined with various targeting moieties, systemic siRNA delivery could be significantly improved.
Our chemistries enable effective cytoplasmic delivery, achieving high efficacy.
SAMiRNA’s unique chemistry significantly reduces innate immune stimulation, which leads to an excellent safety profile.
Our molecule is room temperature stable in solution for up to a year, which means we can potentially save energy and improve access. Patented manufacturing methods make the platform more sustainable than a typical siRNA therapy
siRNAgen Therapeutics
Category:
Venture
Main Business Area
siRNAgen’s pioneering SAMiRNA platform harnesses modular chemistry and self-assembly to expand delivery of RNAi beyond the liver and ultimately make treatments easier on patients. The platform’s unique chemistry leverages supramolecular interactions to form a micellar structure with the oligonucleotide at its core. This design allows the incorporation of specific targeting moieties, broadening the delivery possibilities to target tissues.
| Contact Details |
|---|
